Pasithea Therapeutics (NSDQ:KTTA) announced that it commenced clinical operations with its in-home intravenous ketamine therapy.
Miami Beach, Florida-based Pasithea’s wholly-owned subsidiary, Pasithea Clinics, offers in-home IV ketamine therapy to patients suffering from treatment-resistant mental health issues. The company will offer the treatment initially in New York City, Los Angeles, San Diego and San Francisco, with plans to expand nationwide in the coming months.
Pasithea Therapeutics CEO Dr. Tiago Reis Marques said in a news release that patient safety is a top priority, meaning all treatments will be delivered by board-certified medical professionals. He called it an “important stepping stone” in expanding the company’s international footprint in the space.
“The need for more effective treatment options for patients with mental health disorders has never been greater,” Marques said. “Ketamine, when used at subanesthetic doses, has been shown to be highly effective in treating some psychiatric disorders. Still, we need to broaden access to this treatment to a larger patient population in a safe and convenient way. Through our mobile clinics, patients benefit from receiving the ketamine therapy in the privacy and comfort of their own homes.”
